Biodegradable Polymersomes as Nanocarriers for Doxorubicin Hydrochloride: Enhanced Cytotoxicity in MCF-7/ADR Cells and Prolonged Blood Circulation

Chao, Yanhui; Liang, Yongye; Fang, Guihua; He, Huan; Yao, Qing; Xu, Hui; Yin-rong, Chen; Tang, Xing

doi:10.1007/s11095-016-2088-9

Cited by 20 publications

(9 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The simultaneous encapsulation of 5-FU, Dox and LV eliminates their solution incompatibilities and allows their simultaneous administration with enhanced therapeutic effect. The encapsulation efficiency of all the compounds was greater than 70 % (Table 1) and in agreement with similar studies reported in the literature [41,42].…”

Section: Characterisation and Evaluation Of Polymersomessupporting

confidence: 91%

Electroneutral polymersomes for combined cancer chemotherapy

et al. 2018

View full text Add to dashboard Cite

Combination cancer chemotherapy provides an important treatment tool, both as an adjuvant and neoadjuvant treatment, this shift in focus from mono to combination therapies has led to increased interest in drug delivery systems (DDS). DDSs, such as polymersomes, are capable of encapsulating large amounts of multiple drugs with both hydrophilic and hydrophobic properties simultaneously, as well as offering a mechanism to combat multi drug resistant cancers and poor patient tolerance of the cytotoxic compounds utilised. In this article, we report the formulation and evaluation of a novel electroneutral polymersome capable of high encapsulation efficacies for multiple drugs (Doxorubicin, 5-Fluorouracil and leucovorin). The in-vivo biodistribution of the polymersome were established and they were found to accumulate largely in tumour tissue. Polymersome encapsulating the three chemotherapeutic drugs were assessed both in-vitro (BxPC-3 cell line) and in-vivo (following intratumoral and intravenous administration) and compared with the same concentration of the three drugs in solution. We report better efficacy and higher maximum tolerated dose for our combination drug loaded polymersomes in all experiments. Furthermore, intratumorally injected combination drug loaded polymersomes exhibited a 62% reduction in tumour volume after 13 days when compared with the free combination solutions. A smaller differential of 13% was observed for when treatment was administered intravenously however, importantly less cardiotoxicity was displayed from the polymersomal DDS. In this study, expression of a number of survival-relevant genes in tumours treated with the free chemotherapy combination was compared with expression of those genes in tumours treated with the polymersomes harbouring those drugs and the significance of findings is discussed. STATEMENT OF SIGNIFICANCE: The shift in focus from mono to combination chemotherapies has led to an increased interest in the role of drug delivery systems (DDS). Liposomes, although commercialized for mono therapy, have lower loading capacities and stability than their polymeric counterpart, polymersomes. Polymersomes are growing in prevalence as their advantageous properties are better understood and exploited. Here we present a novel polymersome for the encapsulation of three anticancer compounds. This is the first time this particular polymersome has been used to encapsulate these three compounds with both an in-vitro and in-vivo evaluation carried out. This work will be of interest to those in the field of combination therapy, drug delivery, drug toxicity, multidrug resistance, liposomes, DDS and polymersomes.

show abstract

Section: Characterisation and Evaluation Of Polymersomessupporting

confidence: 91%

Electroneutral polymersomes for combined cancer chemotherapy

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The pharmacokinetic study in male SD rats showed that entrapment of DOX in polymersomes resulted in the prolongation of drug t 1/2 by 4.54-fold, and the increase in AUC by 5.97-fold compared with free drug. These pharmacokinetic changes significantly enhanced cytotoxicity and reduced resistance of MCF-7/ADR cells to DOX 14. An improved pharmacokinetic profile of DOX and its cytotoxicity were also reported when loaded in chitosan-g-TPGS (CT).…”

Section: Resultsmentioning

confidence: 91%

“…The anthracycline antibiotics doxorubicin (DOX) and daunorubicin (DNR) are broadly used for the treatment of a variety of cancers. They exert their action on cancer cells by intercalation into DNA base pairs resulting in blockage of DNA and RNA synthesis and DNA scission, which suppresses the replication of DNA and induces cell apoptosis 14. The pharmacokinetic study in male SD rats showed that entrapment of DOX in polymersomes resulted in the prolongation of drug t 1/2 by 4.54-fold, and the increase in AUC by 5.97-fold compared with free drug.…”

Section: Resultsmentioning

confidence: 99%

<p>Pharmacokinetic studies of nanoparticles as a delivery system for conventional drugs and herb-derived compounds for cancer therapy: a systematic review</p>

Omar

Na‐Bangchang

2019

IJN

View full text Add to dashboard Cite

The poor pharmacokinetic characteristics of most anticancer drugs have limited their clinical effectiveness. The application of nanoparticles as a novel drug delivery system has provided opportunities to tackle the current challenges facing conventional drug delivery systems such as poor pharmacokinetics, lack of specificity to tumor cells, multidrug resistance, and toxicity. This systematic review aims to examine the application of pharmacokinetic studies of nanoparticles loaded in conventional drugs and herb-derived compounds for cancer therapy. The pharmacokinetic parameters of several herbal medicines and chemotherapeutic drugs loaded into nanoparticles were reported. This included area under the curve (AUC) of plasma concentration–time profile, maximum plasma concentration (Cmax), time to maximum plasma concentration (Tmax), volume of distribution (Vd or Vss), elimination half-life (t½), and clearance (CL). The systematic review was conducted using information available in the PubMed and Science Direct databases up to February 2019. The search terms employed were: pharmacokinetics, pharmacokinetic study, nanoparticles, anticancer, traditional medicine, herbal medicine, herb-derived compounds, natural products, and chemotherapy. Overall, nanoparticle carriers not only significantly improved pharmacokinetics but also further enhanced permeability, solubility, stability, specificity, and selectivity of the carried anticancer drugs/herb-derived compounds to target tumor cells. Additionally, they also limited hepatic first-pass metabolism and P-glycoprotein (P-gp) efflux of the carried anticancer drugs/herb-derived compounds. Based on this systematic review, polymeric nanoparticles were the most commonly used nanocarrier to improve the pharmacokinetic parameters. The use of nanoparticles as a novel drug delivery system has the potential to improve both pharmacokinetics and cytotoxicity activity of the loaded drugs/herb-derived compounds for cancer therapy.

show abstract

“…Later on, Chao, et al. successfully generated doxurubicin (DOX)‐loaded polymersomes in nanoscale (60 nm in diameter) by using methoxy poly(ethylene glycol)‐b‐poly(epsilon‐caprolactone) (mPEG‐b‐PCL) . The use of film hydration method for polymersome formation was still very popular, which was being scrutinized in recent reports .…”

Section: Common Methods For Preperation Of Polymeric Hollow Capsulesmentioning

confidence: 99%

Current Advances of Hollow Capsules as Controlled Drug Delivery Systems

Tran

Bhave

2020

ChemistrySelect

View full text Add to dashboard Cite

Polymeric hollow capsules have attracted increasing interest for the development of controlled drug delivery systems due to their capacities to load high amount of drugs and be able to finely tune the drug release profile. Various methods and strategies for capsule preparation and drug loading have been developed over time. Besides that, the controlled drug release from hollow capsules upon external and internal triggers is of great interest and has been a research focus in this area. This article aims to give the most recent progress review on hollow capsule based controlled drug delivery systems with a highlight on strategies being used for drug loading and stimuli-release. In detail, the fabrication of hollow capsules using templateassisted or template-free methods will be introduced first. This will be followed by current strategies for pre-loading and postloading of therapeutic agents into capsules. The article will then be particularly focused on discussing diverse drug-release systems corresponding to various stimuli conditions including temperature, pH, ultrasound, light irradiation and enzyme degradation.

show abstract

Biodegradable Polymersomes as Nanocarriers for Doxorubicin Hydrochloride: Enhanced Cytotoxicity in MCF-7/ADR Cells and Prolonged Blood Circulation

Abstract: The entrapment of DOX in biodegradable polymersomes could enhance cytotoxicity in MCF-7/ADR cells and improve its in vivo pharmacokinetic profile.

Cited by 20 publications

References 40 publications

Electroneutral polymersomes for combined cancer chemotherapy

Electroneutral polymersomes for combined cancer chemotherapy

<p>Pharmacokinetic studies of nanoparticles as a delivery system for conventional drugs and herb-derived compounds for cancer therapy: a systematic review</p>

Current Advances of Hollow Capsules as Controlled Drug Delivery Systems

Contact Info

Product

Resources

About